Novo Nordisk’s Q3 2026 earnings beat driven by Wegovy pill sales

The launch of Wegovy’s oral pill in the UK will drive prescription volumes and revenue in the third quarter of 2026. The pill’s convenience and broader accessibility are expected to outperform analyst expectations for Novo Nordisk’s earnings.

earnings · Prediction Market

Implied probability (Yes)

72%

Closes

2026-10-31

More earnings markets

• Forum AI raises $50M+ in Series B funding by 2027-03-31 — 60% Yes
• Anthropic's compute deal with xAI will underperform revenue targets by Q4 2026 — 70% Yes
• Titleist sells more clubs than Callaway in 2026 — 72% Yes
• Sadi Thermal Machines secures $50M+ funding round by 2027 — 70% Yes
• Lime achieves profitability within 12 months post-IPO — 55% Yes
• SK Hynix ADRs to price at or above midpoint range by July 10 — 75% Yes
• Flexjet stock rises 15% by Q4-2027 on fuel cost advantage — 70% Yes
• Driving instructor revenue drops 15% in Q3 2027 due to test booking changes — 68% Yes

Browse all earnings markets →